Abstract
Respiratory syncytial virus (RSV) is a highly contagious virus that causes pediatric respiratory infections. Most children will contract RSV multiple times throughout childhood, beginning before their first birthday. In many patients RSV infections are minor and self-limiting, but in certain patient populations they can lead to serious complications. Prevention techniques can minimize the spread of RSV. In addition to nonpharmacologic prevention methods, one pharmacologic prevention option, palivizumab, is available for certain patient populations at high risk for complications. Currently, there is a strong need for more preventive and treatment options for RSV.
| Original language | American English |
|---|---|
| Journal | U.S.Pharmacist |
| Volume | 39 |
| State | Published - Jan 1 2014 |
Keywords
- Respiratory syncytial pneumovirus
- article
- clinical feature
- drug cost
- epidemiological data
- high risk population
- human
- nonhuman
- palivizumab
- prevention study
- respiratory syncytial virus infection
- respiratory syncytial virus vaccine
- treatment planning
- upper respiratory tract infection
Disciplines
- Pharmacy and Pharmaceutical Sciences